Class of drugs to lower cholesterol
Statins (or HMG-CoA reductase inhibitors ) are a class of medications that reduce illness and mortality in people who are at high risk of cardiovascular disease .[ 1]
Low-density lipoprotein (LDL) carriers of cholesterol play a key role in the development of atherosclerosis and coronary heart disease via the mechanisms described by the lipid hypothesis . As lipid-lowering medications , statins are effective in lowering LDL cholesterol; they are widely used for primary prevention in people at high risk of cardiovascular disease, as well as in secondary prevention for those who have developed cardiovascular disease.[ 2] [ 3] [ 4]
Side effects of statins include muscle pain , increased risk of diabetes , and abnormal blood levels of certain liver enzymes .[ 5] Additionally, they have rare but severe adverse effects, particularly muscle damage, and very rarely rhabdomyolysis .[ 6] [ 7]
They act by inhibiting the enzyme HMG-CoA reductase , which plays a central role in the production of cholesterol. High cholesterol levels have been associated with cardiovascular disease.[ 8]
There are various forms of statins, some of which include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin , rosuvastatin , and simvastatin .[ 9] Combination preparations of a statin and another agent, such as ezetimibe/simvastatin , are also available. The class is on the World Health Organization's List of Essential Medicines with simvastatin being the listed medicine.[ 10] In 2005, sales were estimated at US$18.7 billion in the United States.[ 11] The best-selling statin is atorvastatin, also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history.[ 12] The manufacturer Pfizer reported sales of US$12.4 billion in 2008.[ 13]
Patient compliance with statin usage is problematic despite robust evidence of the benefits.[ 14] [ 15]
^ "Cholesterol Drugs" . American Heart Association . Archived from the original on 12 August 2020. Retrieved 24 December 2019 .
^ Alenghat FJ, Davis AM (February 2019). "Management of Blood Cholesterol" . JAMA . 321 (8): 800–801. doi :10.1001/jama.2019.0015 . PMC 6679800 . PMID 30715135 .
^ National Clinical Guideline Centre (UK) (July 2014). Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease . National Institute for Health and Clinical Excellence: Guidance. London: National Institute for Health and Care Excellence (UK) . PMID 25340243 . NICE Clinical Guidelines, No. 181. Archived from the original on 29 May 2020. Retrieved 26 April 2020 – via National Library of Medicine .
^ Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G , et al. (January 2013). "Statins for the primary prevention of cardiovascular disease" . The Cochrane Database of Systematic Reviews . 2013 (1): CD004816. doi :10.1002/14651858.CD004816.pub5 . PMC 6481400 . PMID 23440795 .
^ Naci H, Brugts J, Ades T (July 2013). "Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials" . Circulation: Cardiovascular Quality and Outcomes . 6 (4): 390–399. doi :10.1161/CIRCOUTCOMES.111.000071 . PMID 23838105 . S2CID 18340552 .
^ Abd TT, Jacobson TA (May 2011). "Statin-induced myopathy: a review and update". Expert Opinion on Drug Safety . 10 (3): 373–387. doi :10.1517/14740338.2011.540568 . PMID 21342078 . S2CID 207487287 .
^ "Should you be worried about severe muscle pain from statins?" . Mayo Clinic . Archived from the original on 15 May 2024. Retrieved 30 October 2023 .
^ Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. (December 2007). "Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths". The Lancet . 370 (9602): 1829–1839. doi :10.1016/S0140-6736(07)61778-4 . PMID 18061058 . S2CID 54293528 .
^ Sweetman SC, ed. (2009). "Cardiovascular drugs". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press . pp. 1155–1434. ISBN 978-0-85369-840-1 .
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019 . Geneva: World Health Organization . hdl :10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ Taylor FC, Huffman M, Ebrahim S (December 2013). "Statin therapy for primary prevention of cardiovascular disease". JAMA . 310 (22): 2451–2452. doi :10.1001/jama.2013.281348 . PMID 24276813 .
^ Cite error: The named reference Simons
was invoked but never defined (see the help page ).
^ "2008 Annual Report" (PDF) . Pfizer . 23 April 2009. p. 15. Archived (PDF) from the original on 12 May 2013.
^ Maningat P, Gordon BR, Breslow JL (January 2013). "How do we improve patient compliance and adherence to long-term statin therapy?" . Current Atherosclerosis Reports . 15 (1): 291. doi :10.1007/s11883-012-0291-7 . PMC 3534845 . PMID 23225173 .
^ Tarn D, Pletcher M, Tosqui R (June 2021). "Primary nonadherence to statin medications: Survey of patient perspectives" . Preventive Medicine Reports . 22 : 101357. doi :10.1016/j.pmedr.2021.101357 . PMC 8020471 . PMID 33842201 .